BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Asia/Shanghai
BEGIN:STANDARD
TZOFFSETFROM:+0800
TZOFFSETTO:+0800
TZNAME:CST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210608
DTEND;VALUE=DATE:20210611
DTSTAMP:20260515T181418
CREATED:20210203T103911Z
LAST-MODIFIED:20210203T103911Z
UID:28763-1623110400-1623369599@www.pharmajournalist.com
SUMMARY:TCR-based Therapies Summit
DESCRIPTION:The TCR-based Therapies Summit is Dedicated to Supercharging TCR Design\, Translation & Manufacturing Strategy for Solid Tumor Success\nRunning digitally for 2021\, the 2nd TCR-based Therapies Summit is the leading industry-focused meeting dedicated to supercharging the expanded TCR repertoire through enhanced target specificity\, density & binding affinity for solid tumor indications. \n \nThis June (8-10)\, join this exclusive community online to virtually network and learn from the leading experts in pharma\, biotech and academia\, as we discuss how to how to overcome on-target off-tumor toxicity\, enhance the binding affinity and avidity of TCR-T therapies and utilize dual targeting and combination approaches for enhanced efficacy. \nNavigate across 3 days packed with dedicated\, interactive formats exploring the identification of novel targets\, the importance of safety profiling\, and discuss optimization of soluble approaches for the development of next-generation TCR-T products. \nFor more details about the program\, speaker faculty or pricing and discounts\, download the brochure. \nHelping Deliver Best-In-Class TCR Therapies\nJoin experts as they discuss the design\, efficacy and clinical development of TCR therapeutics for solid tumor indications and beyond. \n\nOptimizeyour TCR therapy approach\nExplorenovel combination strategies\nArmyour cells against the hostile tumor microenvironment\nImprovetarget selection and off-target validation\nExplorethe future of manufacturing for next-generation TCRs\n\n“Hanson Wade’s CAR-TCR summit has been already the leading specialized conference in the field – what a great suggestion to set up a dedicated forum for the rapidly growing TCR-T area.” \nSteffen Walter\, Chief Scientific Office\, Immatics US
URL:https://www.pharmajournalist.com/event/tcr-based-therapies-summit/
LOCATION:EST | Digital
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210608
DTEND;VALUE=DATE:20210611
DTSTAMP:20260515T181418
CREATED:20210312T065317Z
LAST-MODIFIED:20210312T065317Z
UID:29307-1623110400-1623369599@www.pharmajournalist.com
SUMMARY:Next Generation Gene Therapy Vectors
DESCRIPTION:The inaugural Next Generation Gene Therapy Vectors meeting is dedicated to overcoming the current immunogenicity\, toxicity and manufacturability challenges facing the field by pioneering the next generation of superior delivery vectors. \n \nIndustry pioneers from cutting edge biotechs and world-leading academic vectorology groups including Dyno Therapeutics\, 4D Molecular Therapeutics and Generation Bio will share how ever-increasing clinical experience is guiding strategies to decrease the immunogenicity of vectors to allow durable transgene expression\, engineer vectors with lower toxicity at higher doses and use innovative technologies to optimise capsid\, transgene\, and promoter design. \nEverything in gene therapy starts with the vector\, so join this definitive\, niche\, digital conference to delve into the details of vector design\, engineering\, and optimization case studies\, equipping you with the insights required to deliver transformative therapeutics to patients more effectively and safely than ever before. \nTo know more about Next Generation Gene Therapy Vectors please click here.
URL:https://www.pharmajournalist.com/event/next-generation-gene-therapy-vectors/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210613
DTEND;VALUE=DATE:20210616
DTSTAMP:20260515T181418
CREATED:20210401T075326Z
LAST-MODIFIED:20210401T075326Z
UID:29614-1623542400-1623801599@www.pharmajournalist.com
SUMMARY:9th PREDiCT: Tumor Models Cell Therapy Summit
DESCRIPTION:With commitments to advancing your preclinical and translational oncology research\, we are delighted to bring the 9th annual PREDiCT: Tumor Models Cell Therapy Summit to your screens in July. \nSee best-in-class tumor models and how they can be effectively utilized to model the tumor microenvironment and further your MoA understanding for new cell therapies. \nLearn to improve your translational and clinical confidence through the use of models to answer critical safety and efficacy questions\, predict toxicity and optimize dosing for patients. \nWhether you work in early discovery or late development\, there is something for all non-clinical professionals with two dedicated tracks: one focused on preclinical modelling and one looking at translational studies. \nBelow are a few highlights you won’t want to miss! \n\nNovartisshare how to use a simple xenograft model to effectively assess CAR-T efficacy\nAstraZenecashows how to guide innovative clinical trials for cell therapies using preclinical data\nTakedadiscuss how to leverage single-cell analytics to understand the complexities of the tumor microenvironment\nHarvard Medical Schoolshare how they use multiple tumor models to advance NK cell therapies\n\nGet involved! Our scientific poster sessions will be returning this year so you can share your latest advances and be apart of the conversation. \nTo know more about 9th PREDiCT: Tumor Models Cell Therapy Summit please click here.
URL:https://www.pharmajournalist.com/event/9th-predict-tumor-models-cell-therapy-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210614
DTEND;VALUE=DATE:20210616
DTSTAMP:20260515T181418
CREATED:20190206T211230Z
LAST-MODIFIED:20200330T122307Z
UID:19393-1623628800-1623801599@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes West Coast
DESCRIPTION:SMi are proud to announce the 5th annual conference:\nPre-Filled Syringes West Coast 2020\n14-15 June 2021\nSan Diego\, CA\, USA\nHyatt Regency Mission Bay\nwww.prefilled-syringes-westcoast.com/pjwl \nAssessing Device Development and Regulation for Advanced Innovation \nSMi is proud to present the 5th Annual Pre-Filled Syringes West Coast Conference in San Diego on 14th and 15th June 2021. \n \nFollowing the success of the last event\, the Pre-Filled Syringes West Coast conference is back to uncover the latest innovations in combination product development\, device design\, human factors engineering and drug product formulation to give a holistic overview of the industry and what we can expect for the future. \nWith the global market for prefilled syringes estimated to exceed $9.7bn by 2025\, this year’s agenda will encompass key drivers and hot topics of the industry including; updates to regulatory guidance from industry experts and regulatory bodies\, case studies on device design and complex formulation\, life cycle and control strategies\, and innovations in connectivity and digital health. \nThis two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more. \nPLUS\, two interactive post conference workshops: \nWorkshop A: Connected devices and digital health: How to navigate the US FDA usability engineering requirements\nHosted by Shannon Clark\, Principal\, UserWise\, Inc. \nWorkshop B: Postmarket safety reporting: The current regulatory environment with a global impact\nHosted by Khaudeja Bano\, Sr. Medical Director\, Abbott Molecular  \nKey Reasons to Attend: \n\nEngage in case study presentations from leading pharma and biotech companies on complex product formulation and optimising device design to aid delivery\nDiscuss show to optimise current processes to align with global regulatory updates\nDelve into human factors engineering best practices\nUncover how industry is incorporating connectivity and digital health to optimise the user experience \n\nWho should attend: \n\nDrug-delivery developers\nMedical Device Engineers\nPrimary Packaging material designers\nSecondary packagers\nSmart device developers\nTraining device developers\nDevice-safety solution providers\nDrug developers \n\nEarly bird deadlines: \n\nRegister by 28th February to save $400\nRegister by 31st March to save $200\nRegister by 30th April to save $100\n\n\nTo register or for more information visit: www.prefilled-syringes-westcoast.com/pjwl \nSOCIAL MEDIA HANDLES \nTwitter: @SMiPharm #Smipfsusa\nLinkedIn: follow our company page – search ‘SMi Pharma’
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-west-coast/
LOCATION:Hyatt Regency Mission Bay\, 1441 Quivira Road\, San Diego\, CA\, 92109\, United States
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210615
DTEND;VALUE=DATE:20210618
DTSTAMP:20260515T181418
CREATED:20210212T080535Z
LAST-MODIFIED:20210212T080535Z
UID:28924-1623715200-1623974399@www.pharmajournalist.com
SUMMARY:2nd RNAi-Based Therapeutics – Digital Summit
DESCRIPTION:As investments and collaborations hit a record high\, the RNAi therapeutics industry continues to rapidly expand. With RNAi drugs prevailing as a therapy with huge potential against liver diseases\, exciting efforts have now turned to a wide range of other diseases\, from CNS\, oncology\, metabolism and more. Despite the growing momentum\, much needs to be addressed in terms of targeted delivery\, safety\, and efficiency to fully unleash the therapeutic value of RNAi drugs. \n \nBuilt with large pharma and pioneering biotech insights\, the 2nd RNAi- Based Therapeutics Summit returns virtually in 2021 to reunite key stakeholders of the field to tap into the full therapeutic opportunity of a wide-range of targeted RNAi therapies with enhanced endosomal escape\, extrahepatic delivery\, & PKPD for CNS\, oncology & beyond. \nWith a number of RNAi based clinical candidates emerging and excitement building in the field\, join the 2nd RNAi Based Therapeutic Summit 2021 – the comprehensive industry guide for senior biopharmaceutical leaders from discovery\, translation & clinical development functions to stay ahead of the race in developing the first targeted extrahepatic RNAi therapy that addresses unmet patient need. \nTo know more about 2nd RNAi-Based Therapeutics please click here.
URL:https://www.pharmajournalist.com/event/2nd-rnai-based-therapeutics-digital-summit/
LOCATION:Digital Event\, EDT
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210616
DTEND;VALUE=DATE:20210618
DTSTAMP:20260515T181418
CREATED:20201020T102522Z
LAST-MODIFIED:20201020T102824Z
UID:27546-1623801600-1623974399@www.pharmajournalist.com
SUMMARY:Skin Microbiome Summit
DESCRIPTION:Skin microbiome products have been gaining more momentum in the last few years with more brands starting to develop products\, and personal care giants either starting to develop their own product or investing in start-ups focusing on these. It is a very exciting time for companies looking into this at the moment\, figuring out not only product development & formulation but also marketing strategy to raise more attention to this type of products. Despite huge popularity and early success stories\, there is still a need to learn more on topics such as: defining the skin microbiome\, formulating products\, cosmetics & pharma claims\, regulation for novel products\, latest advances in terms of mapping & profiling technologies\, as well as product testing. \n \nACI’s Skin Microbiome Industry Summit\, taking place on the 16th & 17th June 2021 in London\, will bring together the key actors of the industry to help the industry learn from one another\, work together to further grow and create new business opportunities. \nDuring the 2 days conference\, the participants will enjoy the various case studies presentations\, panel discussion\, Q&As and networking breaks to get the industry to thrive together. \nJoin us in London for a highly interactive & informative conference\, whilst enjoying the networking opportunities with your peers. \nMembers are entitled to a special discount on registration – to claim please contact Adamantia (Mado) Lampropoulou on MLampropoulou@acieu.net or +44 (0) 203 141 0607 quoting SSMe1MKTG.
URL:https://www.pharmajournalist.com/event/skin-microbiome-summit/
LOCATION:Park Plaza Westminster Bridge 200 Westminster Bridge Rd\, Bishop’s London\, SE1 7UT\, United Kingdom
ORGANIZER;CN="Active Communications International (ACI)":MAILTO:Mlampropoulou@acieu.net
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210617
DTEND;VALUE=DATE:20210619
DTSTAMP:20260515T181418
CREATED:20190131T121650Z
LAST-MODIFIED:20200608T143856Z
UID:19291-1623888000-1624060799@www.pharmajournalist.com
SUMMARY:Pharmaceutical Microbiology West Coast
DESCRIPTION:SMi’s 4th Pharmaceutical Microbiology West Coast Conference \nNovel approaches and best practices for tackling current industry contamination control challenges \nSMi’s 4th Annual Conference Pharmaceutical Microbiology West Coast\nNEW DATE: June 17 – 18\, 2021\nLocation: Hyatt Regency Mission Bay Hotel\, San Diego\, CA\, USA\nWebsite: http://www.pharma-microbiology-usa.com \n \nSPONSORED BY: Associates of Cape Cod\, bioMérieux\, Bioscience International\, Microcoat\, Millipore Sigma and Mettler Toledo \nCo-chairs Jim Polarine\, Senior Technical Service Manager\, STERIS Corporation & Geeta Singh\, Plant and Network Technical Specialist III\, Genentech \nFollowing on the success of the last West Coast event\, SMi proudly presents the 4th Pharmaceutical Microbiology West Coast Conference\, in San Diego\, USA\, on June 17th and 18th 2021 bringing microbiology experts to focus on innovations in rapid methods and contamination control strategies. Microbes such as bacteria\, fungi\, parasites and viruses that can contaminate current and novel pharmaceutical products or therapies may stem from various sources such as raw materials and human operators\, are taken into consideration. \nThis concern is critical in advanced products/therapeutics facilities where often distinct areas within manufacturing are slowly merging\, providing potential new sites for contamination events. The conference showcases sessions that cover alternative endotoxin testing and rapid mycoplasma testing as well as implementation of in-line biodurden monitoring to control water systems\, to name a few. Due to the complexities brought about by more advanced therapeutic products\, both drugs and patients are time dependent and rapid methods are ever more desired. \nA significant portion of the conference will focus on contamination control strategies and facilities support/novel technologies such as a look at a sustainable global contamination control program\, cleanroom pass thru best practices and a case study executing rapid transition from clinical to commercial manufacturing and more. Also see a regulatory session discussing objectionable organisms in non-sterile drug products and an all-women panel discussion: ‘culturing’ successful women microbiologists. \nEvent Hashtag: #SMiPharmaMicroWC \nKEY HIGHLIGHTS FOR 2021 INCLUDE: \n\nDiscuss the guidance\, regulations and case studies for objectionable organisms in non-sterile drug products from ValSource\, Inc.\nGain insight into changing paradigms – moving to in-process testing from Johnson & Johnson\nExamine alternative endotoxin test methods for products exhibiting LER from Amgen\nExplore how to effectively scale up from clinical to commercial in three moves from Bristol-Myers Squibb\nJoin us for our first All-Women Panel Discussion on ‘Culturing’ successful women microbiologists\n\nPlus a half day interactive workshop on Wednesday\, June 16th 2021: \nAfternoon Workshop: Data Integrity in Environmental Monitoring: Causes and Solutions \nLed by: Ziva Abraham\, CEO\, Microrite and Morgan Polen\, SME\, Cleanroom Contamination Control Expert\, Microrite \nView the full agenda: http://www.pharma-microbiology-usa.com \nWHO SHOULD ATTEND \nSenior Microbiologist\, Lead Scientist\, Laboratory Manager\, QA Specialist Drug Substance External Manufacturer\, Business Development Manager – Testing\, Pharmaceutical Microbiology Consultant\, Higher Pharmacopoeia Scientist\, Analytical Standards Specialist \nSOCIAL MEDIA HANDLES \nTwitter: @SMiPharm\nEvent Hashtag: #SMiPharmaMicroWC\nLinkedIn: follow our company page – search ‘SMi Pharma’ \nADDITIONAL CONTACT INFO\nSimi Sapal – Marketing Manager\nPharmaceutical Division – SMi Group Ltd\nT: +44 (0)20 7827 6100\nE: ssapal@smi-online.co.uk
URL:https://www.pharmajournalist.com/event/pharmaceutical-microbiology-west-coast/
LOCATION:Hyatt Regency Mission Bay Hotel\, 1441 Quivira Road\, San Diego\, CA\, CA 92109\, United States
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210617
DTEND;VALUE=DATE:20210618
DTSTAMP:20260515T181418
CREATED:20210617T072629Z
LAST-MODIFIED:20210617T072629Z
UID:30572-1623888000-1623974399@www.pharmajournalist.com
SUMMARY:6th Annual Oncolytic Virotherapy Summit
DESCRIPTION:In its most exciting year yet the field of oncolytic virotherapy has seen the highest number of clinical read-outs\, the emergence of next generation viruses\, and never-before-seen combination therapies. \nNow in its 6th year\, the Oncolytic Virotherapy Summit is the industry’s definitive guide to turning viral vehicles into clinically effective therapeutics across oncology indications. With 3 days of in-depth cutting-edge case studies and the highest caliber of industry discussions\, The OV Summit will provide the roadmap to oncolytic virotherapy market success. \n \nUncover fresh studies from pharma and biotech companies of all sizes\, as well as clinicians and leading academics for a complete picture of the current challenges and opportunities. \nThis year’s Summit will help you to: \n\nUnderstand how viral backbone modification can achieve intravenous delivery\nHarness carefully selected payloads to achieve systemic effects\nScale virus production for commercialization\nThis year\, over 100+ drug developers will converge at the OV Summit to disseminate the latest findings\, build a comprehensive network of like-minded peers who share the same challenges and search for the latest combination and genetic engineering strategies.\n\nJoin the leading minds in oncolytic virus development to optimize the development of viral immunotherapies and improve patient outcomes in combination therapies.
URL:https://www.pharmajournalist.com/event/6th-annual-oncolytic-virotherapy-summit/
LOCATION:Westin Copley Place\, 10 Huntington Ave\, Boston\, MA\, MA 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210622
DTEND;VALUE=DATE:20210625
DTSTAMP:20260515T181418
CREATED:20210315T105128Z
LAST-MODIFIED:20210315T105128Z
UID:29391-1624320000-1624579199@www.pharmajournalist.com
SUMMARY:HER2-Targeted Therapies Summit 2021
DESCRIPTION:Welcome to the Digital HER2-Targeted Therapies Summit 2021 – The First Conference Focused on Exploring New Frontiers of HER2 as a Pan-Tumor Target \nHER2 expressing patients are experiencing drug resistance\, suboptimal duration of response and refractory/relapsed disease\, stimulating new frontiers for HER2-targeted drug development. Impressive clinical data are being reported for next-generation anti-HER2 approaches in breast\, gastric\, lung\, colon cancers and beyond. However\, efforts to expand the clinical utility of HER2 as a pan-tumor target don’t stop there\, with a flood of news on priority reviews\, fast track approvals\, IPOs and collaborations. \nAs such\, the HER2-Targeted Therapies Digital Summit 2021 arrives as the first ever cross-disciplinary meeting for large pharma\, biotech and academia\, to maximize HER2-targeting in the pantumor setting. Expect to be involved in interactive discussions on the diversity of next generation anti-HER2 drugs in the clinic including ADCs\, bispecifics\, TKIs\, CAR approaches & more. \nThis is your chance to overcome challenges of resistance against anti-HER2 approaches and accelerate therapies to patients in need. Examine HER2 heterogeneity across different tumors to maximize the commercial potential of this target. Discuss how quantitative pathology is helping to match HER2 expression with therapeutic response. \nAs the clinical and commercial growth potential of next generation HER2-targeted therapies becomes apparent\, this is a timely and comprehensive forum giving you the opportunity to connect with leaders of the field directly. \nBe part of this unique forum to strengthen your pipeline by expanding the clinical utility of your anti-HER2 candidate across tumor settings with the greatest unmet medical need. \nTo know more about HER2-Targeted Therapies Summit 2021 please click here.
URL:https://www.pharmajournalist.com/event/her2-targeted-therapies-summit-2021/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Shanghai:20210622T150000
DTEND;TZID=Asia/Shanghai:20210622T190000
DTSTAMP:20260515T181418
CREATED:20210602T080240Z
LAST-MODIFIED:20210602T080240Z
UID:30412-1624374000-1624388400@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China E-Trade Season- Sino-India Pharmaceutical Exchange
DESCRIPTION:CPhI & P-MEC China has launched the “E-Trade Season 2021” from March to June 2021 to provide the pharmaceutical industry with online learning and trading opportunities. One of the themed sessions\, named Sino-India Pharmaceutical Exchange\, will be focusing on Indian & Chinese pharma markets\, with online learning and trading opportunities. \nThe live stream webinar will look into policies\, trends and practice\, etc. of both Chinese and Indian pharma markets\, covering topics including Development Trend of China’s API Industry and Cooperation Prospect with India\, Requirements and Practical Procedures of Imported Drug Registration in China\, and Development of Indian APIs and Generic Drugs in Indian and Chinese Market\, with guest speakers from China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE)\, China Chinopharma Limited\, and Dr. Reddy’s Laboratories. \nThe webinar is FREE for anyone to register and attend. Registered attendees will receive access to the webinar.
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-e-trade-season-sino-india-pharmaceutical-exchange/
LOCATION:Online
ORGANIZER;CN="Informa Markets":MAILTO:tinny.yao@imsinoexpo.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210628
DTEND;VALUE=DATE:20210701
DTSTAMP:20260515T181418
CREATED:20210402T091212Z
LAST-MODIFIED:20210406T095308Z
UID:29618-1624838400-1625097599@www.pharmajournalist.com
SUMMARY:3rd Annual Blood-Brain Barrier Summit
DESCRIPTION:Now in its 3rd year\, the Blood-Brain Barrier Summit is the industry’s definitive blood-brain barrier conference\, focused exclusively on evaluating innovative approaches to tackling the single biggest challenge for CNS drug developers. \nBuilding on the success of last year’s meeting\, this year’s program will uncover how leading companies and academics are working to enhance BBB penetration through the use of antibody therapies\, nanoparticle engineering\, AAV capsids\, focused ultrasound\, extracellular vesicles and more! New for this year we also explore the mechanisms of SARS-CoV-2 brain entry. \nAs we gather the best minds in this ever-challenging field\, from the likes of AbbVie\, Novartis\, Roche\, Merck and Ossianix\, join this intimate forum to be part of the conversation focused on enhancing drug delivery across the blood-brain barrier and network and build meaningful partnerships with over 80 blood-brain barrier specialists. \nTo know more about 3rd Annual Blood-Brain Barrier Summit please click here.
URL:https://www.pharmajournalist.com/event/blood-brain-barrier-summit-2021/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210629
DTEND;VALUE=DATE:20210702
DTSTAMP:20260515T181418
CREATED:20210301T091950Z
LAST-MODIFIED:20210301T091950Z
UID:29192-1624924800-1625183999@www.pharmajournalist.com
SUMMARY:6th Microbiome Movement - Drug Development Summit
DESCRIPTION:Close the Clinical Gap\, Discover the Next Generation of Microbiome-based Therapeutics\, and Establish New Partnerships to Accelerate Your Research \nThe advancing scientific and clinical landscape mixed with the high-quality audience that we bring together has made this the must attend conference for those translating microbiome science into clinically successful therapeutics. \nThere is increased excitement around this years’ discussion; the community is now closer than ever to the first approved and commercially available microbiome-based therapeutic\, key functions are beginning to be understood and the number of clinical candidates are increasing. However\, there still remains an abundance of significant hurdles that must be overcome in order for continued success to be seen within the microbiome field. We are proud to bring together those at the forefront of tackling those challenges and is once again the centre of the 6th Microbiome Movement – Drug Development Summit. \n \nThe Microbiome Movement will provide the perfect opportunity for a collaborative approach between the biopharmaceutical and academic communities in order to pursue the causal role of the microbiome in disease and develop a new generation of microbiome-targeted therapeutics with predictable modes of action and consistent clinical outcomes. \nFrom understanding microbiome functionality\, leveraging lessons from clinical development and scaling manufacturing processes\, through to leveraging microbiome biomarkers for patient stratification and diagnostics\, our discussion will cover the latest scientific findings and industry updates from the end-to-end development of microbiome therapeutics. \nThere is still so much we can continue to do to make this complex science a clinical reality that improves the lives of patients\, and we hope that you can join this years’ discussion to help towards the development of effective treatments across a range of indications and push microbiome products closer to commercialization. \nTo know more about 6th Microbiome Movement – Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/6th-microbiome-movement-drug-development-summit/
LOCATION:Virtual
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210629
DTEND;VALUE=DATE:20210702
DTSTAMP:20260515T181418
CREATED:20210309T092319Z
LAST-MODIFIED:20210309T092319Z
UID:29289-1624924800-1625183999@www.pharmajournalist.com
SUMMARY:Induced Proximity-Based Drug Discovery Summit
DESCRIPTION:Since the start of the 20th century\, there have been three major waves of innovation in drug discovery. We are now at the start of a fourth wave\, multispecific medicines\, that will pave the way for new treatments aimed at thousands of disease targets currently viewed as “undruggable”. By inducing proximity between two or more proteins\, multispecifics can harness the power of biology to go well beyond what conventional drugs can achieve. \n \nAs such\, the inaugural Induced Proximity-Based Drug Discovery Summit arrives as the dedicated scientific and networking forum for large pharma\, innovative biotech and research institutes to seize the endless potential of induced proximity- based drug discovery strategies to develop novel therapies for paradigm changing multispecific drugs of the future. \nJoin 100+ thought leaders of Chemically Biology\, Screening Biology and Molecular Biology from the likes of Amgen\, Ranok Therapeutics\, Proxygen and more at the Induced Proximity- Based Drug Discovery Summit to advance your knowledge\, differentiate your pipelines and be at the forefront of this new wave of innovation that will revolutionize drug discovery as currently known. \nTo know more about Induced Proximity-Based Drug Discovery Summit please click here.
URL:https://www.pharmajournalist.com/event/induced-proximity-based-drug-discovery-summit/
LOCATION:EST | Digital
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210629
DTEND;VALUE=DATE:20210702
DTSTAMP:20260515T181418
CREATED:20210312T075616Z
LAST-MODIFIED:20210312T080030Z
UID:29331-1624924800-1625183999@www.pharmajournalist.com
SUMMARY:JAK Inhibitors Drug Development Summit
DESCRIPTION:Returning to the digital stage this summer\, the 2nd JAK Inhibitors Drug Development Summit brings you the only dedicated JAK inhibitor conference that will allow you to utilize the knowledge of the greatest minds and thought leaders within the realms of the JAK pathway across dermatology\, rheumatology\, gastroenterology\, oncology and hematology. \nFocusing on optimized selectivity\, drug-drug interactions\, safety and efficacy challenges\, this summit will give you the insight to successfully translate and develop the next generation of superior JAK inhibitors. \nEnsure you attend this conference to learn\, to network and to strengthen your pipeline\, and implement the right clinical strategy.
URL:https://www.pharmajournalist.com/event/jak-inhibitors-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210630
DTEND;VALUE=DATE:20210702
DTSTAMP:20260515T181418
CREATED:20210331T084111Z
LAST-MODIFIED:20210331T110431Z
UID:29602-1625011200-1625183999@www.pharmajournalist.com
SUMMARY:3rd Cell Engager Summit
DESCRIPTION:The 3rd Annual Cell Engager Summit is the only industry-led forum dedicated to developing multi-specific cell engaging therapies in liquid and solid tumor indications\, accelerating early discovery innovation into the clinic. \nThis forum comes at a critical point for the cell engager field as the success observed in the hematological field has not been obtained with solid tumors yet. Preclinical and early clinical data for cell engagers targeting solid tumors have been hugely promising. \nIf you are part of a research team that is looking to accelerate the approval of cell engager therapies\, then this conference has been curated with you in mind. \nBelow are a few highlights you won’t want to miss: \n\nDrive efficacy in solid tumors with solid tumor targets addressed by Roche\, Amgen\, Pfizer\, Merus\, andCompass Therapeutics\nModulate the immune system to drive efficacy via co-stimulatory targets in solid tumors with Xencor\, Harbour Biomed\, Crescendo Biologics\, Pieres\,and Aptevo\nHarness the power of the innate system for cell engagers and overcome the tumor microenvironment with Merck\, Lava Therapeutics\, Verseau Tx\, andoNKo-Innate\nImproving the therapeutic window of cell engagers – addressing toxicity\, half-life\, and CRS withAmunix\, Synaffix\, Revitope\, and TeneoBio\n\nTo know more about 3rd Cell Engager Summit please click here.
URL:https://www.pharmajournalist.com/event/3rd-cell-engager-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR